Samar Sankari, MD
Endocrinology, Diabetes & Metabolism · Charleston, WVNPI 1013947241
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 405 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations.
Across 405 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$2K
- Novo Nordisk$1K
- Lilly USA, LLC$985
- Sanofi-aventis U.S. LLC$697
- Abbott$651
- Amgen$558
- plus $2K from 22 others
What the payments were for
- Food & beverage$7,42598%
- Education$1322%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 50 | $1,606 |
| Novo Nordisk | 82 | $1,183 |
| Lilly USA, LLC | 70 | $985 |
| Sanofi-aventis U.S. LLC | 35 | $697 |
| Abbott | 47 | $651 |
| Amgen | 16 | $558 |
| AstraZeneca | 15 | $212 |
| Boehringer Ingelheim | 12 | $206 |
| Amarin Pharma, Inc. | 14 | $196 |
| Medtronic(2 entities) | 5 | $183 |
| AbbVie | 10 | $173 |
| Johnson & Johnson | 10 | $146 |
| Xeris Pharmaceuticals, Inc. | 5 | $94 |
| Insulet Corporation | 5 | $88 |
| Corcept Therapeutics | 6 | $87 |
| Amneal Pharmaceuticals LLC | 4 | $65 |
| Janssen Scientific Affairs, LLC | 1 | $65 |
| Tandem Diabetes Care, Inc. | 2 | $64 |
| Merck | 4 | $58 |
| Cequr Corporation | 1 | $58 |
| IBSA Pharma Inc. | 2 | $44 |
| EUSA Pharma (US) LLC | 2 | $30 |
| Recordati_rare_diseases_inc. | 2 | $30 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Sequel Med Tech, LLC | 1 | $17 |
| Bayer | 1 | $16 |
| Antares Pharma, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$250
- SOLIQUA 100/33$100
How this compares
$7,558 in reported general payments places this provider in the 80th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
See all endocrinology, diabetes & metabolism providers in West Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 760 | $991,233 |
| JardianceEmpagliflozin | 510 | $646,838 |
| MounjaroTirzepatide | 280 | $368,889 |
| TrulicityDulaglutide | 205 | $305,474 |
| Tresiba Flextouch U-200Insulin Degludec | 151 | $208,540 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 174 | $198,637 |
| TradjentaLinagliptin | 141 | $134,994 |
| Novolog FlexpenInsulin Aspart | 340 | $120,909 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 62 | $115,438 |
| FarxigaDapagliflozin Propanediol | 75 | $96,540 |
| Tresiba Flextouch U-100Insulin Degludec | 67 | $70,450 |
| SynthroidLevothyroxine Sodium | 708 | $68,505 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 248 | $46,515 |
| Humalog Kwikpen U-100Insulin Lispro | 119 | $34,082 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 210 | $31,943 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,183 | $1,020,420819 claims |
| Boehringer IngelheimJardiance, Tradjenta | $206 | $781,831651 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $985 | $686,512542 claims |
| AstraZenecaFarxiga | $212 | $96,54075 claims |
| AbbVieSynthroid | $173 | $68,505708 claims |
| MerckJanuvia | $58 | $23,73716 claims |
| Johnson & JohnsonInvokana | $146 | $12,86619 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $65 | $9,943929 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $697 | $9,76011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
Other endocrinology, diabetes & metabolism in Charleston
- Brian AprillCharleston$6K
- Lee Ann SkaffCharleston$2K
- Nicholas CassisCharleston$2K
- Ilia BernsteinCharleston$2K
- Steven ArtzCharleston$1K
- Raghda SahloulCharleston$558
- Glenn CrottyCharleston$422
- Stephen GrubbCharleston$198
- Daniel MaciasHuntington$686K
- Zachary KistkaMartinsburg$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.